Clinical Trial Update: Rash & Diarrhea Prophylaxis With Capivasertib [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating rash and diarrhea prophylaxis with capivasertib in metastatic hormone receptor-positive, HER2-negative breast cancer; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Capivasertib (capivasertib)

Snippet

Sponsor: Maryam Lustberg | Conditions: Metastatic HR+/HER2- Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING